Clovis Oncology Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Clovis Oncology does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
n/a
Ausschüttungsquote
| Durchschnittlicher Branchenertrag | 1.9% |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | n/a |
| Gewinn pro Aktie | -US$1.73 |
| Prognose der Dividendenrendite | 0% |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if CLVS.Q's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if CLVS.Q's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
| Clovis Oncology Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (CLVS.Q) | n/a |
| Untere 25 % des Marktes (US) | 1.4% |
| Markt Top 25 % (US) | 4.3% |
| Branchendurchschnitt (Biotechs) | 1.9% |
| Analystenprognose (CLVS.Q) (bis zu 3 Jahre) | 0% |
Bemerkenswerte Dividende: Unable to evaluate CLVS.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate CLVS.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as CLVS.Q has not reported any payouts.